Abstract
We have heard convincing evidence this morning of the alterations in plasma lipids induced by a broad range of oral contraceptive preparations. Because of the epidemiological association between atherosclerotic cardiovascular disease and hyperlipoproteinemia, hypertriglyceridemia as well as hypercholesterolemia (1), and the possibility that progestational agents may therefore limit the relative immunity from atherosclerosis enjoyed by premenopausal women, we have begun to explore the mechanism of the hypertriglyceridemia of oral contraceptive therapy. These studies, then, evaluate the altered balance between triglyceride (TG) input and removal which result in a raised plasma TG concentration in women given oral progestational agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
